Post-authorisation, multicentric, observational, retrospective and prospective study to assess quality of care of sarcoma patients in expert and non-expert centers by analysing correlation of quality items and outcomes such as relapse free survival, overall survival, percentage of amputation, etc.
Expert pathology peer review will be performed to detect differences between expert and non-expert centers as well as differences in treatment and patient prognosis.
Tumor samples of 4 types of sarcoma would also be included in translational research to detect biomarkers and produce preclinical models.
Histological diagnosis of soft-tissue sarcoma, GIST or bone sarcoma (all subtypes) from January 2005 until Juny/September 2023.
≥ 18 years
Available clinical and treatment information
None
Soft-tissue sarcoma, Gastrointestinal stromal tumor (GIST) Bone sarcoma (all subtypes)
Case-only
Other
Quality assessment
Other interventionThere is no intervention on study subjects. A tumor review will be performed by expert centers.
Percentage of cases with > 5 cm with tru-cut biopsies.
tumor should be bigger than 5cm
Percentage of biopsies carried out by sarcoma teams vs not sarcoma team
in all the series and in cases with \> 5 cm
Percentage of patients with image studies at diagnosis and before surgery.
The same type of image should have been performed
Percentage of patients discussed in Multidisciplinary Team before treatment
multidisciplinary team includes serval departments at the same center
Surgical margins
using Enneking
Relapse-free survival
days of survival from date of first line treatment until progression or death
Overall survival
Days from diagnosis (date of biopsy or first pathology report) until death whatever cause.
Percentage of amputation
Resection of any member.
Click on the lead sponsor to view all of their trials.
